Abingdon Health – full-year results argue “well placed”. Er, what about the cash burn?!
By Steve Moore | Thursday 24 November 2022
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Describing itself as “a leading international developer and manufacturer of high quality, rapid diagnostic tests”, Abingdon Health (ABDX) has announced results for its year ended 30th June 2022 with CEO Chris Yates arguing “as a knowledge leader in lateral flow, and with our comprehensive contract service offering, we believe we are well-placed to support customers in bringing their products to market and grow our business”. So why are the shares currently 12.5% lower today to 5.25p?
You must be a registered member to read this story
ShareProphets is reader-supported journalism
Join us for free and gain access to three articles per month
Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.